

1 Original Research Article

2 **Antifungal activity of citral by disruption of**

3 **ergosterol biosynthesis in fluconazole resistant**

4 ***Candida tropicalis***

5

6 **ABSTRACT**

7

A limited number of antifungals and the emergence of resistant strains have hindered the treatment of candidiasis, making the search for new antifungals urgent. Citral is a monoterpene with known pharmacological properties, including antimicrobial action. **Aims:** Thus the objective of this study was to investigate the possible mechanism of citral's action against *Candida tropicalis* isolated from human blood, and the effect of its association with antifungals. **Methodology:** The minimum inhibitory concentration (MIC), the minimum fungicidal concentration (MFC), the effect of citral on the cell wall (sorbitol assay), and membrane ergosterol binding were evaluated using broth microdilution technique. We also evaluated interference in ergosterol biosynthesis, and the citral-antifungal association effect (checkerboard method). **Results:** The MIC₉₀ and MFC₉₀ of citral were respectively 512 and 1024 µg / mL. The MIC of citral did not increase when sorbitol or ergosterol was added to the medium, suggesting that citral does not act on the cell wall or by membrane ergosterol binding. However, citral inhibited ergosterol biosynthesis, and the citral-fluconazole combination showed synergistic effects for the ATCC strain. **Conclusion:** This study contributes to understanding the antifungal mechanism of citral's action, and to the development of new therapies for candidiasis treatment.

8

9 *Keywords: Mode of action, monoterpene, antifungal activity, candidiasis, ergosterol.*

10

11

12 **1. INTRODUCTION**

13

14 Invasive fungal infections with alarming mortality rates have increased significantly in recent

15 decades [1]. More than 70% of invasive fungal infections in hospitalized patients are caused

16 by *Candida spp.*, presenting predominantly as candidemia [2]. Although *Candida albicans* is

17 the most common species associated with invasive candidiasis, non - *C. albicans* species

18 are increasingly common [3-5]. This is a concern because resistance to fluconazole and

19 amphotericin B is higher in non-*albicans* species than *C. albicans* [6].

20

21 *Candida tropicalis* is often found in intensive care unit patients, especially those who require

22 prolonged catheterization, receive broad-spectrum antibiotics, or suffer from cancer [7- 10].

23 *C. tropicalis* also seems to exhibit a great potential for dissemination in neutropenic patients

24 [7]. According to some epidemiological studies, *C. tropicalis* is associated with higher

25 mortality than *C. albicans* or other non - *C. albicans* species [3, 7, 11, 12].

26

27 The three major classes of antifungal agents used to treat invasive fungal infections are the

28 polyenes, the azoles, and the echinocandins. Polyenes (such as the amphotericin B) bind to

29 ergosterol, the main sterol of fungal cell membranes, forming pores that increase the

30 permeability of the membrane, which leads to cell death. Azoles interrupt ergosterol

31 biosynthesis, inhibiting the enzyme lanosterol 14 α -demethylase and consequently inhibiting

32 fungal replication. Echinocandins in turn, inhibit the synthesis of β -1,3-D-glucan, an integral

component of the fungal cell wall, causing a weakening of the fungal cell wall, cell lysis, and death [13, 14].

Of the few available antifungal agents to treat invasive fungal infections, unfortunately, azoles are usually fungistatic rather than fungicidal and prolonged use contributes to the development of resistance [15]. Polyenes, despite having low resistance rates are very toxic. Lipid formulations of amphotericin B, (less toxic than conventional amphotericin B), and the echinocandins, (a new antifungal class), are both prohibitively expensive [13, 16]. Thus, development of new antifungal drugs, and new therapeutic strategies are urgently needed [1]. Plant-derived antifungal compounds are attracting great interest as natural alternatives, due in part to their versatile applications [17, 15].

Citral (3,7-dimethyl-2,6-octadienal) is a natural mixture of two acyclic monoterpene aldehyde geometric isomers, geranial (trans-citral or citral A), and neral (cis-citral or citral B). It is present in the essential oil of many plants including lemon and orange species [18, 19]. Citral presents different pharmacological properties, such as: anti-tumor [20- 22], bronchodilator [23], antiprotozoal [24], and antimicrobial [19, 25- 34] effects.

Although there are many reports on the antimicrobial properties of citral, there are few studies on its antifungal modes of action, or its combination with antifungals against strains of *Candida tropicalis*. The objective of this study was to investigate the antifungal activity of citral against *C. tropicalis*, its possible mechanism of action, and its effect in combination with antifungal agents.

2. MATERIAL AND METHODS

2.1 Chemicals

Sorbitol, ergosterol, citral, fluconazole, and amphotericin B were purchased from Sigma-Aldrich, Brazil. The drugs were solubilized in 5% dimethylsulfoxide (DMSO), and 2% Tween 80 (Sigma-Aldrich). Next, sterile distilled water was added, and the tubes mixed for 5 min using a Vortex (Fanem), to obtain the desired concentrations.

2.2 Microorganisms

The assays were performed with one standard strain of *Candida tropicalis* ATCC 13803, which is part of the Collection of the Mycology Laboratory, Department of Pharmaceutical Sciences, Center of Health Sciences, Federal University of Paraíba, and 7 clinical strains of *C. tropicalis* (1, 6, 18, 20, 23, 31 and 36) isolated from blood, provided by Professor Everardo Albuquerque Menezes (Department of Clinical Analyses, Ceará Federal University).

Cultures of strains were made in Sabouraud dextrose agar (Difco Lab., USA), and incubated at 35 °C for 24-48 h. Colonies of this culture were suspended in sterile 0.85% NaCl, and the inoculum was standardized to the 0.5 tube of the McFarland scale ($1-5 \times 10^6$ CFU/mL).

2.3 Determination of minimum inhibitory concentration (MIC), and minimum fungicidal concentration (MFC)

The MIC was determined by the microdilution technique in broth medium. RPMI-1640, with L-glutamine (Sigma-Aldrich®, São Paulo, SP, Brazil) without sodium bicarbonate was added to all wells of the 96-well plates. Next, serial dilutions of the citral were made to obtain

concentrations varying between 1024 and 0.5 µg/mL. The same procedure was carried out with fluconazole and amphotericin B. DMSO (5%) and Tween 80 (2%), without drugs, served as control. Finally, 10 µL of yeast inoculum was added to all wells, and the plates were incubated at 35 °C for 24 - 48 h. The MIC was defined as the lowest concentration capable of visually inhibiting the fungal growth seen in the wells [35].

To determine the MFC, after reading the MIC aliquots of 20 µL from each of the wells with no fungal growth were seeded in a Sabouraud dextrose agar containing plate, which was then incubated at 37 °C for 24–48 h. The MFC was the lowest drug concentration that showed either no growth, or fewer than three colonies [36]. The assays were performed in triplicates, and the geometric mean values were calculated.

Based on the MIC and MFC results, two representative strains were selected, for the subsequent assays, a clinical strain (*C. tropicalis* 18), and a standard strain (*C. tropicalis* ATCC 13803).

2.4 Sorbitol and ergosterol effect assay

The MIC of citral was determined with *C. tropicalis* 18 and ATCC 13803 by the microdilution method [35], in the absence and presence of 0.8 M of sorbitol, and 400 µg/mL of ergosterol. Amphotericin B was used as a control drug for the ergosterol tests. The plates were read at 48 h and after 5 days [37]. The assays were performed in triplicate and the geometric mean values were calculated.

2.5 Sterol quantitation assay

For extraction of total sterol content of the *C. tropicalis* ATCC 13803 cells, 1 mL of inoculum was added to 9 mL of Sabouraud dextrose broth (Difco Lab., USA), containing MIC/2, MIC, and 2 x MIC of citral, the MIC of fluconazole (as positive control), and for negative control (no test compound). The cultures were incubated for 24 h at 35 °C. The fungal cells were then centrifuged at 3,000 rpm for 5 min, washed once with sterile distilled water, and the wet weight of the cell pellet was determined. Three milliliters of 25% alcohol/potassium hydroxide solution (25 g of KOH and 35 mL of sterile distilled water, brought to 100 mL with 100% ethanol), was added to each pellet and vortex-mixed for 1 min. Cell suspensions were incubated in 85 °C water bath for 1 h and then allowed to cool at room temperature. Sterols were then extracted by addition of a mixture of 1 mL of sterile distilled water and 3 mL of n-heptane followed by vigorous vortexing for 3 min. The heptane layer was transferred to Eppendorf tubes and stored under refrigeration for 24 h. Aliquots of the sterol extracts were examined by measuring the absorbance at 281.5 nm and 230 nm with a UV-visible spectrophotometer (Shimadzu). This assay was performed in triplicate. Ergosterol content was calculated as the percentage of the wet weight of cell, as reported by Arthington-Skaggs [38]. The results were expressed in mean ± SE. Statistical analyses were performed with the *t*-test. *P* ≥ 0.05 was considered significant.

2.6 Checkerboard method

Combinations of citral- fluconazole, and citral- amphotericin B were tested in triplicate against *C. tropicalis* 18, and ATCC 13803 using microdilution checkerboard technique [39]. The concentration of each antifungal agent tested ranged from 1/16 to 8 × MIC. The initial inoculum was prepared as described for broth-microdilution susceptibility testing. The inoculated plates were incubated at 35°C for 24 h. The MIC endpoints were determined as described for the broth-microdilution tests. To determine the activity of the drug combinations, fractional inhibitory concentration (FIC) indices were calculated as $FIC^A + FIC^B$, where FIC^A and FIC^B represent the minimum concentrations that inhibited bacterial

growth for the drugs A and B, respectively: $FIC^A = MIC^A \text{ combination} / MIC^A \text{ alone}$, and $FIC^B = MIC^B \text{ combination} / MIC^B \text{ alone}$. A mean FIC index was calculated based on the following equation: $FIC \text{ index} = FIC^A + FIC^B$, and the interpretation was made as follows: synergistic (≤ 0.5), additive (>0.5 but <1), indifferent (≥ 1 but <4), or antagonistic (≥ 4.0) [39].

3. RESULTS AND DISCUSSION

The MIC and MFC results against 7 clinical strains of *C. tropicalis* (1, 6, 18, 20, 23, 31, and 36), isolated from blood, and 1 standard strain (*C. tropicalis* ATCC 13803) are shown in Table 1.

Table 1. MIC of citral, fluconazole, and amphotericin B; and MFC of citral against *C. tropicalis*.

<i>Candida tropicalis</i>	Citral ($\mu\text{g/mL}$)		Fluconazole ($\mu\text{g/mL}$)	Amphotericin B ($\mu\text{g/mL}$)	Control strains ^a
	MIC	MFC	MIC	MIC	
1	512	512	> 1024	2	+
6	512	1024	> 1024	1	+
18	512	1024	> 1024	1	+
20	512	1024	> 1024	1	+
23	512	512	> 1024	1	+
31	256	256	> 1024	0.5	+
36	512	1024	512	1	+
ATCC 13803	512	1024	64	1	+

^a microorganism growth in RPMI-1640, DMSO (5%), and Tween 80 (2%), without antifungal or monoterpenes.

The anti-*Candida* citral potential was previously demonstrated by diffusion in solid medium technique against *C. albicans*, *C. tropicalis*, *C. parapsilosis*, *C. krusei*, *C. glabrata*, *C. stellatoidea*, and *C. guilhermondii* [26, 28, 33]. The essential oil of *Cymbopogon citratus*, whose main constituent is citral, also showed antifungal activity against *C. albicans*, *C. parapsilosis*, and *C. tropicalis* by disk diffusion method [40]. In *C. albicans*, Lima et al. [29] reported a citral MIC of 512 $\mu\text{g/mL}$, while Leite et al. [27] obtained an MIC of 64 $\mu\text{g/mL}$. Mesa-Arango et al. [31] reported an MIC of 125 $\mu\text{g/mL}$ against *C. parapsilosis*,

The MIC of fluconazole was 64 $\mu\text{g/mL}$ for the ATCC strain and > 1024 $\mu\text{g/mL}$ for 6 of the 7 clinical strains, while the MIC of amphotericin B ranged from 0.5 to 2 $\mu\text{g/mL}$ (Table 1).

According to the NCCLS [35], strains exhibiting an MIC for fluconazole of $\geq 64 \mu\text{g/mL}$ are considered to be resistant, and strains with an MIC for amphotericin B of $\geq 2 \mu\text{g/mL}$ are considered resistant. Thus, according to this classification, resistance to fluconazole was observed for all strains tested, and resistance to amphotericin B for one strain, *C. tropicalis* 1 (Table 1).

Amphotericin B and fluconazole are among the most widely used antifungal agents for the treatment of systemic fungal infections [41]. Fluconazole is widely used in clinical practice due to its efficacy and low toxicity [42], however, with frequent exposure, fluconazole-

resistant *Candida* isolates have appeared more often [43-45]. According to Barchiesi et al. [46], and Calvet et al. [47], fluconazole drug resistance in *C. tropicalis* develops much faster than in *C. albicans*.

Four principal mechanisms of azole resistance have been described in *Candida* spp.: reducing drug penetration and decreased intracellular concentration through activation of drug efflux pumps; change in the target site structure on the enzyme (ERG11 gene); increased concentration of the target enzyme; and development of alternative pathways (ERG3 gene) [48].

The MFC of citral varied between 256 and 1024 $\mu\text{g/mL}$. Both the MFC₅₀ (Minimum Fungicidal Concentration for 50% of strains tested), and the MFC₉₀ (Minimum Fungicidal Concentration for 90% of strains tested) for citral were 1024 $\mu\text{g/mL}$ (Table 1).

According Hafidh et al. [49] the MFC/MIC ratio is used to specify the nature of the antimicrobial effect against a particular pathogen. When the MFC/MIC ratio is between 1:1 and 2:1, the chemical is considered fungicidal. On the other hand, if the ratio is > 2:1, it is more likely to be fungistatic. In the present study, the MFC/MIC ratios of citral were 1 or 2; this suggests that citral has a fungicidal effect against the strains tested. In strains of *C. albicans*, Leite et al. [27], and Zore et al. [50] also reported the fungicidal effect of citral, using the kill time method. Fungicidal activity is clinically more important than fungistatic activity. The prophylactic use of fungistatic drugs has been associated with an increased frequency of innate or acquired resistance in clinical isolates [51].

Two major fungal structures are important targets of antifungal agents: the cell wall and the plasma membrane. To investigate whether citral acts on fungal cell walls, sorbitol testing was performed. Sorbitol, an osmotic protective is used to stabilize the yeast protoplasts. This test compares the MIC values of the antifungal product in the absence and presence of 0.8 M sorbitol. A distinctive feature of drugs that act by inhibiting the synthesis of fungal cell walls is that their antifungal effect is reversed in a medium containing an osmotic stabilizer such as sorbitol [52]. If the product somehow acts on the cell wall, it causes the lysis of yeast cells in the absence of an osmotic stabilizer, but allows growth in the presence of an osmotic medium [37]. And this effect is detected by an increase in the MIC value in media containing sorbitol, as compared to the MIC of media without sorbitol [53].

In this work, when strains of *C. tropicalis* were treated with citral in a medium supplemented with sorbitol, the MIC values did not increase (Table 2), suggesting that citral does not act by inhibiting fungal cell wall synthesis, but probably by affecting another target.

Table 2. MIC ($\mu\text{g/mL}$) of drugs in the absence and presence of sorbitol and ergosterol against *C. tropicalis*.

Drugs	<i>C. tropicalis</i> 18			<i>C. tropicalis</i> ATCC 13803		
	Without sterols ^a	With sorbitol	With ergosterol	Without sterols ^a	With sorbitol	With ergosterol
Citral	512	512	512	512	512	512
Ampho B ^b	1	-	128	1	-	128

^aThe results are expressed as geometric mean of three experiments. ^bPositive control - Not tested.

219 This is the first study to demonstrate the action of citral on the cell wall of *C. tropicalis* using
220 sorbitol tests. The results are in agreement with those reported by Leite et al. [27] and Lima
221 et al. [29] who have shown that citral does not act on the cell wall of *C. albicans*. Since it
222 appears that citral does not act at the level of the fungal cell wall, another possibility
223 investigated was that it might act at the level of the cell membrane. Some antifungal agents
224 interfere with plasma membrane ergosterol by forming complexes, or by inhibiting
225 membrane biosynthesis [54, 55].
226

227 To investigate whether citral binds ergosterol in fungal membranes of *C. tropicalis*, the MIC
228 of this monoterpene was determined with and without the addition of ergosterol to the
229 medium. If the antifungal activity of citral is caused by binding to ergosterol, the exogenous
230 ergosterol prevents binding to ergosterol in the fungal cell membrane. As a result there is an
231 MIC increase in the presence of exogenous ergosterol compared to the control [37].
232

233 As can shown in Table 2, the MIC value of citral was not altered in the presence of
234 exogenous ergosterol, suggesting that citral does not act by binding to membrane
235 ergosterol. Amphotericin B, a positive control having a known interaction with ergosterol [37],
236 showed a MIC value about 100 times greater in the presence of sterol (Table 2). There are
237 few studies on the direct interaction of citral with ergosterol of the fungal cell membrane.
238 However, in *C. albicans*, Leite et al. [27], and Lima et al. [29] did not observe changes in the
239 MIC of citral in the presence of exogenous ergosterol.
240

241 Considering ergosterol is an important fungal cell membrane lipid, changes in its biosynthetic
242 pathway may also cause damage to the fungal cell, preventing growth in a way similar to
243 azole compounds, or similar to fluconazole [38]. To examine whether citral interferes with the
244 biosynthesis of ergosterol in *C. tropicalis* cells, it was necessary to quantify the content of
245 sterols produced by the strains in the presence of this monoterpene in different
246 concentrations (MIC/2, MIC, and MIC x 2), and of fluconazole (at its MIC). For this, it was
247 necessary to analyze the absorption of sterols extracted from fungal cultures at the
248 wavelengths of 230, and 281.5 nm. Ergosterol and an intermediate of the metabolic pathway
249 of ergosterol - 24(28) dehydroergosterol (DHE) absorb energy at 281.5 nm, but (DHE) alone
250 shows intense absorption at 230 nm. Changes in this pattern of absorption are indicative of
251 interference in the synthetic pathway of ergosterol [56].
252

253 The results were expressed as % ergosterol biosynthesis inhibition in the absence (control),
254 and presence of fluconazole (at MIC), and citral (at MIC/2, MIC, and MIC x 2) (Figure 1).
255




Fig. 1. Percentage of ergosterol biosynthesis inhibition in the absence (control), and presence of citral at MIC/2, MIC, and MIC x 2, and fluconazole at MIC against *C. tropicalis* ATCC (a) $p<0.05$ compared to control; (b) $p<0.05$ compared to fluconazole.

As can be seen, fluconazole (used as a positive control), was able to inhibit ergosterol biosynthesis in fungal cells significantly ($p<0.05$) compared to the control (no drug), while citral at MIC and MIC x 2 inhibited ergosterol biosynthesis ($p<0.05$ as compared to the control). Both concentrations were as potent as fluconazole ($p>0.05$).

These results indicate a possible mechanism of action for citral mediated inhibition of ergosterol biosynthesis, similar to the azoles. However, in contrast to the fungistatic nature of fluconazole, citral appears to have fungicidal nature [27, 50]. Using this methodology in investigating the mechanism of action of citral on the species *C. tropicalis* has not been reported in the literature, and this study is the first such report. Recent studies have shown that citral inhibits ergosterol biosynthesis in *C. albicans* [57], and *Penicillium italicum* [58]. Ergosterol biosynthesis inhibition has also been observed for citral at 200 µg/mL in *Aspergillus ochraceus* [59].

According Zore et al. [50] citral also causes S phase cell cycle arrest, and induction of apoptosis in strains of *C. albicans*. In a recent study by Zhou et al. [60], citral inhibited mycelial growth in *Geotrichum citri-aurantii*, and its antifungal activity was attributed to a disruption of cell membrane integrity, and loss of cellular components. Combining antifungal drugs may improve therapeutic response. The potential benefits of using therapeutic combinations include a broader spectrum of efficacy, improved cure rates, safety, and tolerability, reduction of resistance to antifungal drugs, dose reduction, and thus reduced toxicity [61].

Thus, after investigating the mode of action, we evaluated the effect of citral in association with the antifungal fluconazole, and amphotericin B against *C. tropicalis* strains, using the checkerboard technique. The results are shown in Table 3.

Table 3. MIC* of citral and effect of combination with antifungals against *C. tropicalis*

Citral + Antifungal	<i>C. tropicalis</i> 18		<i>C. tropicalis</i> ATCC 13803	
	MIC	FIC* index	MIC (µg/mL)	FIC* index

	(µg/mL)	(type of interaction)		(type of interaction)
Citral	512		512	
Amphotericin B	1		1	
Fluconazole	> 1024		64	
Citral/Amphotericin B	128/0.5	0.75 (additive)	256/0.5	1.0 (indifferent)
Citral/Fluconazole	-	-	128/16	0.5 (synergic)

*MIC, minimal inhibitory concentration; *FIC, fractional inhibitory concentration.

As can be seen, the citral-amphotericin B combination was additive (FICI = 0.75) for the clinical strain, and indifferent (FICI = 1.0) for the ATCC strain, while the citral- fluconazole combination was synergistic (FICI = 0.5) against the ATCC strain. The clinical strain of *C. tropicalis* was not evaluated with the citral-fluconazole combination because the MIC of fluconazole was greater than 1024 µg/mL. Fortunately, no antagonistic actions were observed for the combinations studied.

The fact that the citral-amphotericin B combination present different results for the ATCC and clinical strains of the same species (*C. tropicalis*) (Table 3) can be explained in part, by the fact that each strain displays a variety of types of resistance according to the environment and substances to which it has already been exposed. According to published reports, the effect of combining amphotericin B and flucytosine, for example, has varied between synergism and antagonism, and also changes according to the species, and even which strain is tested [62, 63].

The focus of this evaluation is of the efficacy of combination antifungal drugs with respect to the extent or rate of death of the fungal pathogen, although other potential interactions (such as pharmacokinetic drug interactions), may well impact efficiency when agents are used together [63].

There are few studies on the citral-antifungal associations against *C. tropicalis* strains. However, in *C. albicans* strains, previous studies have shown synergistic effects for citral-fluconazole [64, 50], and for citral-amphotericin B; effects ranging from indifferent to synergistic [64].

There are several synergistic activity mechanisms involved in antifungal combinations: inhibition of the fungal intracellular pathways essential for cell survival in different stages; increased penetration of the antifungal agent provided by the action of the another cell membrane antifungal; inhibition of protein carriers; simultaneous inhibition of different cellular targets [63].

4. CONCLUSION

The results of this study demonstrate that citral shows antifungal activity against strains of fluconazole resistant *C. tropicalis* isolated from blood, increasing the arsenal of products with anti-Candida activity. The citral-fluconazole combination showed synergistic effects. The likely mechanism of citral's action appears not to involve cell walls, or binding to membrane ergosterol, but is likely mediated through inhibition of ergosterol biosynthesis. This study represents an advance in our understanding of citral's antifungal mechanisms of action. However, more studies are needed to investigate whether citral also acts on other targets in the fungal cell.

333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385

CONSENT

All the authors declare that no consent was obtained for this study.

ETHICAL APPROVAL

For this study was considered the ethical and legal aspects of research involving human subjects in this study (including human material or human data) is in compliance with the Helsinki Declaration (<http://www.wma.net/en/30publications/10policies/b3/index.html>). Patient data involved in the research are confidential and sensitive, ensuring respect for privacy and anonymity of the subjects. It was not possible to obtain written informed consent of each patient, since this is a retrospective study. The research was conducted with the approval of the Research Ethics Committee of University Hospital Lauro Wanderley of the Federal University of Paraíba, Brazil, reference number 0295/11.

REFERENCES

1. Castelli MV, Butassi E, Monteiro MC, Svetaz LA, Vicente F, Zacchino SA. Novel antifungal agents: a patent review (2011-present). *Expert Opin Ther Pat.* 2014; 24: 323-38.
2. Horn DL, Fishman JA, Steinbach WJ, Anaissie EJ, Marr KA, Olyaei AJ, et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. *Diagn Microbiol Infect Dis.* 2007; 59: 407-14.
3. Jordan I, Hernandez L, Balaguer M, Castilla JDL, Casanueva L, Shuffelman C, et al. *C. albicans*, *C. parapsilosis* and *C. tropicalis* invasive infections in the PICU: clinical features, prognosis and mortality. *Rev Esp Quimioter.* 2014; 27: 56-62.
4. Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast infections. *Lancet Infect Dis.* 2011; 11: 142-51.
5. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo, J. *Candida glabrata*, *Candida parapsilosis* and *Candida tropicalis*: biology, epidemiology, pathogenicity and antifungal resistance. *FEMS Microbiol. Rev.* 2012; 36: 288-305.
6. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. *Int J Antimicrob Agents.* 2006; 27:359-66.
7. Colombo AL, Guimarães T, Silva LRBF, Monfardini LPDA, Cunha AKB, Rady P, et al. Prospective Observational Study of Candidemia in São Paulo, Brazil: Incidence Rate, Epidemiology, and Predictors of Mortality. *Infection Control and Hospital Epidemiology.* 2007; 28: 570-6.
8. Kauffman CA, Vazquez JA, Sobel JD, Gallis HA, McKinsey DS, Karchmer AW, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. *Clin Infect Dis.* 2000; 30: 14-8.
9. Nucci M, Colombo AL. Candidemia due to *Candida tropicalis*: clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals. *Diagn Microbiol Infect Dis.* 2007; 58: 77-82.

- 386 10. Rho J, Shin J, Song J, Park M, Kee S, Jang S, et al. Molecular investigation of two
387 consecutive nosocomial clusters of *Candida tropicalis* candiduria using pulsed-field gel
388 electrophoresis. J Microbiol. 2004; 42: 80–6.
389
- 390 11. Eggimann P, Garbino J, Pittet D. Epidemiology of *Candida* species infections in critically
391 ill nonimmunosuppressed patients. Lancet Infect Dis. 2003; 3: 685–702.
392
- 393 12. Kontoyiannis DP, Vaziri I, Hanna HA, Boktour M, Thornby J, Hachem R, et al. Risk
394 Factors for *Candida tropicalis* fungemia in patients with cancer. Clin Infect Dis. 2001; 33:
395 1676–81.
396
- 397 13. Chandrasekar P. Management of invasive fungal infections: a role for polyenes. J
398 Antimicrob Chemother. 2011; 66: 457–65.
399
- 400 14. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends
401 Microbiol. 2003; 11: 272–9.
402
- 403 15. Khan A, Ahmad A, Akhtar F, Yousuf S, Xess I, Khan LA, et al. *Ocimum sanctum*
404 essential oil and its active principles exert their antifungal activity by disrupting ergosterol
405 biosynthesis and membrane integrity. Res Microb. 2010; 161: 816–23.
406
- 407 16. Neoh CF, Slavin M, Chen SCA, Stewart K, Kong DCM. Echinocandins in the treatment
408 of candidaemia and invasive candidiasis: clinical and economic perspectives.
409 Int J Antimicrob Agents. 2014; 43: 207–14.
410
- 411 17. Ahmad A, Khan A, Manzoor N, Khan LA. Evolution of ergosterol biosynthesis inhibitors
412 as fungicidal against *Candida*. Microb. Pathog. 2010; 48: 35–41.
413
- 414 18. Fisher K, Phillips C. Potential antimicrobial uses of essential oils in food: is citrus the
415 answer? Trend in Food Sci & Technol. 2008; 19: 156–64.
416
- 417 19. Saddiq AA, Khayyat SA. Chemical and antimicrobial studies of monoterpene: Citral.
418 Pesticide Biochem and Physiol. 2010; 98: 89–93.
419
- 420 20. Chaouki W, Leger DY, Liagre B, Beneytout JL, Hmamouchi M. Citral inhibits cell
421 proliferation and induces apoptosis and cell cycle arrest in MCF-7 cells. Fundam Clin
422 Pharmacol. 2009; 23: 549–56.
423
- 424 21. Dudai N, Weinstein Y, Krup M, Rabinski T, Ofir R. Citral is a new inducer of caspase-3 in
425 tumor cell lines. Planta Med. 2005; 71: 484–8.
426
- 427 22. Xia H, Liang W, Song Q, Chen X, Chen X, Hong J. The in vitro study of apoptosis in NB4
428 cell induced by citral. Cytotechnol. 2013; 65: 49–57.
429
- 430 23. Mangprayool T, Kupittayanant S, Chudapongse N. Participation of citral in the
431 bronchodilatory effect of ginger oil and possible mechanism of action. Fitoterapia. 2013; 89:
432 68–73.
433
- 434 24. Cardoso J, Soares J. In vitro effects of citral on *Trypanosoma cruzi* metacyclogenesis.
435 Mem Inst Oswaldo Cruz. 2010; 105: 1026–32.
436

25. Belda-Galbis CM, Pina-Pérez MC, Leufvén A, Martínez A, Rodrigo D. Impact assessment of carvacrol and citral effect on *Escherichia coli* K12 and *Listeria innocua* growth. Food Cont. 2013; 33: 536 - 44.
26. Ferreira TM, Silva FS, Teodoro GR, Costa ACBP, Maria A, Beltrame Júnior M, et al. Citral antifungal activity against *Candida* genus yeasts isolated from hospitalized patients. Rev Inst Adolfo Lutz. 2009; 68: 118-25.
27. Leite MCA, Bezerra APB, Sousa JP, Guerra FQS, Lima EO. Evaluation of Antifungal Activity and Mechanism of Action of Citral against *Candida albicans*. Evid Based Complement Alternat Med. 2014; 11: 1-9.
28. Lima IO, Oliveira RAG, Lima EO, Souza EL, Farias NP, Navarro DF. Inhibitory effect of some phytochemicals in the growth of yeasts potentially causing opportunistic infections. Brazilian J Pharm Sci. 2005; 41: 199-203.
29. Lima IO, Nóbrega F M, Oliveira WA, Lima EO, Menezes E A, Cunha FA, et al. Anti-*Candida albicans* effectiveness of citral and investigation of mode of action. Pharm Biol. 2012; 50: 1536-41.
30. Luo M, Jiang LK, Huang YX, Xiao M, Li B, Zou GL. Effects of citral on *Aspergillus flavus* spores by quasielastic light scattering and multiplex microanalysis techniques. Acta Biochim Biophys Sin. 2004; 36: 277-83.
31. Mesa-Arango AC, Montiel-Ramos J, Zapata B, Durán C, Betancur-Galvis L, Stashenko E. Citral and carvone chemotypes from the essential oils of Colombian *Lippia alba* (Mill.) N.E. Brown: composition, cytotoxicity and antifungal activity. Mem Inst Oswaldo Cruz. 2009; 104: 878.
32. Park MJ, Gwak KS, Yang I, Kim KW, Jeung EB, Chang JW, et al. Effect of citral, eugenol, nerolidol and alpha-terpineol on the ultrastructural changes of *Trichophyton mentagrophytes*. Fitoterapia. 2009; 80: 290-6.
33. Silva CB, Guterres SS, Weisheimer V, Schapoval EES. Antifungal activity of the lemongrass oil and citral against *Candida* spp. Braz J Infect Dis. 2008; 12: 63-6.
34. Somolinos M, García D, Condón S, Mackey B, Pagán R. Inactivation of *Escherichia coli* by citral. J Appl Microbiol. 2009; 108: 1928-39.
35. CLSI: Clinical and Laboratory Standards Institute: *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Second Edition*. CLSI document M27-A2. Wayne, PA: CLSI; 2002.
36. Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol. 2002; 40: 3776-81.
37. Escalante A, Gattuso M, Pérez P, Zacchino S. Evidence for the mechanism of action of the antifungal phytolaccoside B isolated from *Phytolacca tetramera* Hauman. J Nat Prod. 2008; 71: 1720-5.

489 38. Arthington-Skaggs BA, Warnock DW, Morrison CJ. Quantitation of *Candida albicans*
490 ergosterol content improves the correlation between *in vitro* antifungal susceptibility test
491 results and *in vivo* outcome after fluconazole treatment in murine model of invasive
492 candidiasis. Antimicrob Agents Chemother. 2000; 44: 2081-5.
493

494 39. Lewis RE, Diekema DJ, Messer SA, Pfaller MA, Klepser ME. Comparison of Etest,
495 chequerboard dilution and time-kill studies for the detection of synergy or antagonism
496 between antifungal agents tested against *Candida* species. J Antimicrob Chemother. 2002;
497 49: 345-51.
498

499 40. Soares MO, Vinha AF, Barreira SVP, Coutinho F, Aires-Gonçalves S, Oliveira MBPP, et
500 al. Evaluation of Antioxidant and Antimicrobial Properties of the Angolan *Cymbopogon*
501 *Citratus* Essential Oil With a View to Its Utilization as Food Biopreservative. J Agric Sci.
502 2013; 5: 36-45.
503

504 41. Almeida AA, Mesquita CSS, Svidzinski TIE, Oliveira KMP. Antifungal susceptibility and
505 distribution of *Candida* spp. isolates from the University Hospital in the municipality of
506 Dourados, State of Mato Grosso do Sul, Brazil. Rev Soc Bras Med Trop. 2013; 46: 335-9.
507

508 42. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, et al. Results from
509 the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis
510 of susceptibilities of *Candida* species and other yeast species to fluconazole and
511 voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2007;
512 45: 1735-45.
513

514 43. Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaeldgaard P, Knudsen JD, et al.
515 Epidemiological changes with potential implication for antifungal prescription
516 recommendations for fungaemia: data from a nationwide fungaemia surveillance
517 programme. Clin Microbiol Infect. 2013; 19: E343-E53.
518

519 44. Mulu A, Kassu A, Anagaw B, Moges B, Gelaw A, ALemayehu M, et al. Frequent
520 detection of 'azole' resistant *Candida* species among late presenting AIDS patients in
521 northwest Ethiopia. BMC Infect Dis. 2013; 13: 82.
522

523 45. Shuyuan L, Hou Y, Chen X, Gao Y, Li H, Sun S. combination of fluconazole with non-
524 antifungal agents: apromising approach to cope with resistant *candida albicans* infections
525 and insight into new antifungal agent discovery. Int J Antimicrobial Agents. 2014; 43: 395-
526 402.
527

528 46. Barchiesi F, Calabrese D, Sanglard D, Falconi DF, Caselli F, Giannini D, et al.
529 Experimental induction of fluconazole resistance in *Candida tropicalis* ATCC 750. Antimicrob
530 Agents Chemother. 2000; 44: 1578-84.
531

532 47. Calvet HM, Yeaman MR, Filler SG. Reversible fluconazole resistance in *Candida*
533 *albicans*: a potential in vitro model. Antimicrob Agents Chemother. 1997; 41: 535-9.
534

535 48. Peman J, Canton E, Espinel-Ingroff A. Antifungal drug resistance mechanisms. Expert
536 Rev Anti Infect Ther. 2009; 7: 453-60.
537

538 49. Hafidh RR, Abdulamir AS, Vern LS, Bakar FA, Abas F, Jahanshiri F, et al. Inhibition of
539 growth of highly resistant bacterial and fungal pathogens by a natural product. Open
540 Microbiol J. 2011; 5: 96-106.
541

50. Zore GB, Thakre AD, Jadhav S, Karuppayil SM. Terpenoids inhibit *Candida albicans* growth by affecting membrane integrity and arrest of cell cycle. *Phytomed*. 2011; 18: 1181-90.
51. Monk BC, Goffeau A. Outwitting multidrug resistance to antifungals. *Sci*. 2008; 321: 367-9.
52. Frost DJ, Brandt KD, Cugier D, Goldman R. A whole-cell *Candida albicans* assay for the detection of inhibitors towards fungal cell wall synthesis and assembly. *J Antibiot*. 1995; 28: 306-9.
53. Svetaz L, Agüero MB, Alvarez S, Luna L, Feresin G, Derita M, et al. Antifungal activity of *Zuccagnia punctata* Cav.: evidence for the mechanism of action. *Planta Med*. 2007; 73: 1074-80.
54. Czub J, Baginski M. Comparative molecular dynamics study of lipid membranes containing cholesterol and ergosterol. *Biophys J*. 2006; 90: 2368-82.
55. Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal infections. *Int J Microbiol*. 2012; 2012: 1-26.
56. Moran PG, Pinjon E, Coleman DC, Sullivan DJ. Analysis of drug resistance in pathogenic fungi. In: *Medical Mycology: cellular and molecular techniques*. England: John Wiley & Sons Ltd; 2007.
57. Rajput SB, Karuppayil SM. "Small molecules inhibit growth, viability and ergosterol biosynthesis in *Candida albicans*". *SpringerPlus*. 2013; 2: 1-6.
58. Tao N, Ouyang Q, Jia L. Citral inhibits mycelial growth of *Penicillium italicum* by a membrane damage mechanism. *Food Control*. 2014; 41: 116-21.
59. Hua H, Xing F, Selvaraj J. N, Wang Y, Zhao Y, Zhou L, et al. Inhibitory Effect of Essential Oils on *Aspergillus ochraceus* Growth and Ochratoxin A Production. *PloS one*. 2014; 9: 1-10.
60. Zhou H, Tao N, Jia L. Antifungal activity of citral, octanal and α -terpineol against *Geotrichum citri-aurantii*. *Food Control*. 2014; 37: 277-83.
61. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. Combination treatment of invasive fungal infections. *Clin Microbiol Rev*. 2005; 18: 163-94.
62. Cuenca-Estrella M. Combinations of antifungal agents in therapy - what value are they? *J Antimicrob Chemother*. 2004; 54: 854-60.
63. Johnson MD, Macdougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination Antifungal Therapy. *J Antimicrob Chemother*. 2004; 48: 693-715.